Please login to the form below
45
Revenue 2017Zytiga
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Zytiga was produced by Janssen.
Generic threat looms to J&J’s blockbuster Zytiga in US
Zytiga will enter the market and will result in a significant decline in sales.”. ... J&J isn’t the only company that would be affected by an early generic Zytiga launch.
Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use
The expanded licence will help it compete with J&J’S rival treatment Zytiga, which has also been broadening into patients with earlier stage disease.
Daily Brief: NICE says no to Zytiga, Genentech and UK biotech sign microbiome deal
UK Market Access. NICE says no to Zytiga. NICE has rejected Janssen’s Zytiga plus androgen deprivation therapy (ADT) for men with untreated high-risk hormone-sensitive metastatic prostate cancer (mHSPC). ... Around half of patients unable to tolerate
EMA starts review of Xtandi in non-metastatic prostate cancer
At the moment Xtandi - like longstanding rival Zytiga (abiraterone acetate) from Johnson &Johnson - is only prescribed for men with advanced CRPC that has spread and no longer responds to hormone therapy.
PROSPER data reveal big Xtandi benefit in early-stage prostate cancer
At the moment Xtandi, in common with a rival therapy from Johnson &Johnson called Zytiga (abiraterone acetate), is only prescribed for men with advanced CRPC that has spread and no longer ... The market category will see some significant disruption later
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Featured jobs
-
Account Director
-
Competitive Salary Offered
-
Experienced Medical Writers
-
Competitive Salary and Benefits
-
Associate Medical Director
-
Excellent PTO, bonus and 401k package
- Principal Health Economist - North-West
-
Negotiable
- Manager - Immunology, Therapeutic Area Communications & Publ...
-
Competitive Salary Offered
-
Medical (Scientific) Director
-
£120, 000 benefits
- Senior Account Executive with progression to Account Manager, Me...
-
Excellent package
- CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...
-
EXCELLENT DAY RATES AVAILABLE
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Account Manager
-
Negotiable
-
Medical Writer
-
Bonus Scheme, PTO &Private Healthcare
-
Medical Writer
-
Salary TBC
-
Associate Director
-
£75, 000-90, 000
- Business Development Director – Health Education
-
excellent commission
- Account Executive/ Senior Account Executive
-
competitive Salary Offfered
-
Business Director
-
Competitive Salary Offered
Subscribe to our email news alerts
- NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done
- Dragonfly signs Celgene as partner for NK cell platform
- NICE appraisal fees to be introduced despite opposition
- AZ still sees route to approval for Imfinzi in MYSTIC trial
- AstraZeneca’s oncology renaissance
- New editor adds microscopic attention to detail at Porterhouse Medical
PMHub
Hanson Zandi
Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...
Latest intelligence
- AstraZeneca’s oncology renaissance
- Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
- Navigating the antibiotic resistance crisis
- Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
- Combined immunotherapies – potential and pitfalls
- ‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Quick links
Infographics
